Table 1.
Shape/size | Modification | Cell line | Uptake/location | Behavior/differentiation | Damage/toxicity | Molecules involved | Signal pathway | References |
---|---|---|---|---|---|---|---|---|
Rod 55 nm | Serum protein | A549, 16HBE MSC cells | Clathrin-mediated, from lysosome to mitochondria | Morphological change | Selective lysosomal membranes and actin damage | ROS | Mitochondrion-related pathway | [31] |
Sphere 4 nm | PMA layer | HUVECs, C17.2 cells, PC12 cells | Active endocytosis | Cell cycle arrest | Cytoskeleton damage | Focal adhesion kinase, ROS | Actin-mediated pathway | [133] |
Sphere, rod, urchin, 10–80 nm | PEG, CTAB | Microglia neural cells, transgenic mouse | Shape-dependent | N | Autophagy phagocytosis | IL-1 α, TLR-2 TNF-α, GM-CSF | Pro-inflammatory signals | [134] |
Sphere 5, 10, 20 nm | PAA, PDHA | HL-60, HEK293 THP-1 | N | N | Inflammation | Mac-1, IL-8, TNF-α | Mac-1 receptor pathway | [28] |
Sphere 20 nm | Negative charged | MSCs osteoblast cells | Receptor-mediated endocytosis | MSCs toward osteoblast cells | Mechanical stress | p38 | p38 MAPK pathway | [121] |
NPs 20 nm | FBS | MRC-5 human lung fibroblasts | Endosomes, lysosomes | Autophagosome | Oxidative damage | ROS MAP-LC3 | LKB1-AMPK signal pathway | [135] |
Sphere 10, 25, 50 nm | Negatively charged | Normal rat kidney cells | Size-dependent endocytosis | N | Lysosome impairment | LC3, p62 | Autophagic pathway | [35] |
NPs 5, 20, 50, or 100 nm | Unmodified | EOC, A2780, OVCAR5, SKOV3-ip, OSE | Size-dependent endocytosis | Inhibition of tumor growth and metastasis | N | TSG-14, MMP 8, bFGF, TGF-β, E-cadherin, HB -GFs | p38-MAPK pathways, EMT | [136] |
Au NRs | PSS, SiO2 | NG108-15 neuronal cells | N | Differentiation | N | Ca2+ | Ca2+ signal | [32] |
Au NPs 2.7 nm | Tiopronin | MCF-7,HeLa L929, H520 | Endosomes, lysosomes, perinuclear areas | N | Cytotoxicity depends on dose | ROS | N | [126] |
Spherical Au NPs 21 nm | N | Male C57BL/6 mice, | Abdominal fat tissue, liver | N | No cytotoxicity | TNFα, IL-6 | Inflammation related | [137] |
A NR | Cetyltrimethylammonim bromide | A549, 16HBE | Mitochondria, lysosome | Metabolic change | Oxidative stress, mitochondria damage | Lactate GSH GSSG | Metabolic pathway | [113] |
Au NRs 62.3 nm | PDDAC, PSS, PEG | MEF-1, MRC-5 | Lysosome | N | Depend on dose and cell types | Bach-1, HO-1, ROS, | HO-1 pathways | [128] |
Au NPs | PEG-silane layer, cRGD, PEG-diacrylate (PEG-DA) hydrogels | Hematopoietic KG-1a, REF52 | N | Cell adhesion | Affect cell behavior | N | N | [130] |
Au NPs | Single citrate capped | A549 | Lysosome | Cycle arrest at the G0/G1 phase | Aggregation of the MTs, apoptosis | Bax, p53, Bcl-2, PARP | Apoptosis-related pathway | [118] |
N: not mentioned. EOC: epithelial ovarian cancer. OSE: ovarian surface epithelial. A549: human alveolar adenocarcinoma epithelial cells. 16HBE: normal bronchial epithelial cells. MEF-1: mouse embryo fibroblast cell line. MRC-5: human embryonal lung fibroblast cell line. REF52: rat embryonic fibroblast. PDDAC: poly (diallyldimethyl ammonium chloride). PSS: polyethylene glycol and polystyrene sulfonate. HO-1: heme oxygenase-1. MTs: microtubules. PARP: poly (ADP-ribose) polymer. MSCs: mesenchymal stem cells. PMA: a phorbol 12-myristate 13-acetate.